CRVUSD is trading at $0.999381, close to the $1 reference level, and is up 0.09659% over 24 hours. Its 24-hour range of $0.99821 to $0.99956 is narrow, with the current price near the high; this indicates limited recent price movement rather than a pronounced directional breakout.

The short-term price change is positive, but the longer snapshots lean slightly negative: CRVUSD is down 0.0445% over seven days, 0.0377% over 14 days, and 0.009% over 30 days. These are small moves, so they point to mild recent weakness, not a strong downward trend.

Hourly moving averages are tightly grouped between $0.9992 and $0.9995, consistent with the narrow price range. The 8-, 13-, 21-, and 55-hour averages are at or just below the current price, while the 144-hour average at $0.9995 is slightly above it; this is a mixed, low-separation signal rather than clear directional confirmation.

The hourly RSI of 67 supports stronger very short-term momentum, in line with the positive 24-hour change and price near its daily high. However, the seven-day RSI of 49 is close to neutral, so the stronger hourly reading has not translated into a clearly positive weekly momentum signal.

The supplied volume is 5,181,918, and volume relative to market capitalization is 2.45%. These figures describe activity, but without a historical comparison they do not establish whether participation is increasing or unusually high, and they do not resolve the mixed price and momentum readings.

The all-time high is $1.11, well above the current quote, but that historical extreme alone does not indicate a likely direction for the present price. The more relevant supplied evidence is the current near-$1 trading level, narrow range, and modest changes across the seven-, 14-, and 30-day periods.

Overall rating: Hold. Near-$1 stability and a positive 24-hour move are counterbalanced by slightly negative multiweek changes, a near-neutral seven-day RSI, and moving averages that provide no decisive trend signal; the elevated hourly RSI is a short-term positive, but not enough to outweigh that mixed evidence.